Biotechnology

Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program

Retrieved on: 
Monday, May 16, 2022 - 8:30am
Science, Women, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical Trials, Risk, IVF, Infertility, Urine, Degenerative disease, AMH, Woman, Health, Endometriosis, Life expectancy, PCOS, Bayer, AMHR2, Program, Biomarker, Polycystic ovary syndrome, Ovary, Osteoporosis, Menopause, Evotec, Primary ovarian insufficiency, CEO, Pharmaceutical industry, Birth control

The program, which was a product of Celmatixs decade-long focus on identifying novel biomarkers and drug targets for womens health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy.

Key Points: 
  • The program, which was a product of Celmatixs decade-long focus on identifying novel biomarkers and drug targets for womens health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy.
  • Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment.
  • A century ago, the average life expectancy for women globally was under 50, so most women did not live long enough to experience menopause.
  • The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.

Immunovia strengthens its US team through the appointment of Natalie Carfora as Head of Market Access US

Retrieved on: 
Monday, May 16, 2022 - 7:49am
People, Risk, Patient satisfaction, Nasdaq, Patient, Health, Myriad Genetics, Pharmacy, Genetics, Boston University School of Public Health, Biotechnology, Questrom School of Business, Head, Adoption, Business administration, Pancreatic cancer, Growth, Market access, CEO, Pharmaceutical industry

LUND, Sweden, May 16, 2022 /PRNewswire/ --Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Natalie Carfora as Head of Market Access of its US subsidiary, Immunovia, Inc. Natalie brings deep expertise to the reimbursement process from prior market access roles at Scipher Medicine and Myriad Genetics.

Key Points: 
  • LUND, Sweden, May 16, 2022 /PRNewswire/ --Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Natalie Carfora as Head of Market Access of its US subsidiary, Immunovia, Inc. Natalie brings deep expertise to the reimbursement process from prior market access roles at Scipher Medicine and Myriad Genetics.
  • "The hire of Natalie as Head of Market Access in the US is another key hire in-line with our strategic priority to strengthen our US team for a commercial scale up of IMMray PanCan-d in the US.
  • Adding her talents to the team is another important step in driving the adoption and growth of IMMray PanCan-d," says Jeff Borcherding, CEO of Immunovia, Inc, Immunovia AB's US subsidiary.
  • Natalie Carfora brings over ten years of sales and market access experience across biotechnology, medical device, and pharmaceutical industries to the team.

Immunovia strengthens its US team through the appointment of Natalie Carfora as Head of Market Access US

Retrieved on: 
Monday, May 16, 2022 - 7:46am
People, Risk, Patient satisfaction, Nasdaq, Patient, Health, Myriad Genetics, Pharmacy, Genetics, Boston University School of Public Health, Biotechnology, Questrom School of Business, Head, Adoption, Business administration, Pancreatic cancer, Growth, Market access, CEO, Pharmaceutical industry

LUND, Sweden, May 16, 2022 /PRNewswire/ --Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Natalie Carfora as Head of Market Access of its US subsidiary, Immunovia, Inc. Natalie brings deep expertise to the reimbursement process from prior market access roles at Scipher Medicine and Myriad Genetics.

Key Points: 
  • LUND, Sweden, May 16, 2022 /PRNewswire/ --Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Natalie Carfora as Head of Market Access of its US subsidiary, Immunovia, Inc. Natalie brings deep expertise to the reimbursement process from prior market access roles at Scipher Medicine and Myriad Genetics.
  • "The hire of Natalie as Head of Market Access in the US is another key hire in-line with our strategic priority to strengthen our US team for a commercial scale up of IMMray PanCan-d in the US.
  • Adding her talents to the team is another important step in driving the adoption and growth of IMMray PanCan-d," says Jeff Borcherding, CEO of Immunovia, Inc, Immunovia AB's US subsidiary.
  • Natalie Carfora brings over ten years of sales and market access experience across biotechnology, medical device, and pharmaceutical industries to the team.

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

Retrieved on: 
Monday, May 16, 2022 - 6:30am
Security, Data Management, Technology, Pharmaceutical, General Health, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Software, Networks, Internet, Research, Health, Senior, QIAGEN, Risk, DNA, Blood, QGEN, U.S. Securities and Exchange Commission, Urinary tract infection, Bacteria, Solution, Knowledge, HUS, Molecular diagnostics, Research, Life, RNA, Budget, STEC, Automation, Protein, SEC, Hemolytic–uremic syndrome, Growth, Laboratory, NYSE, Chlamydia pneumoniae, Vaccine, Academy, Insight, Pharma

The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.

Key Points: 
  • The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.
  • The launch of QIAstat-Dx Rise syndromic testing platform provides automated, comprehensive pathogen testing for higher-demand medical institutions, said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN.
  • QIAstat-Dx Rise and its test cartridges are a closed system for hands-off sample preparation and processing.
  • Building on the existing QIAstat-Dx Analyzer with up to four analytical modules, QIAstat-Dx Rise is a flexible new option for increased testing capacity.

Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5

Retrieved on: 
Monday, May 16, 2022 - 7:00am
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Muscular dystrophy, ANSM, Health care, EST, EMA, FKRP, Master of Science, European Society of Gene and Cell Therapy, Therapy, Research, National Medicinal Drugs Policy, CMC, Lists of diseases, Orphan, Quality, Supply chain, Vaccine, Patient, Degenerative disease, CTA, European Medicines Agency, Cell, MBA, Sanofi Pasteur, CNRS, LGMD, Poster, MHRA, Date, Technology, CTO, Orphan drug, Hope, Gene, Industry, AAV, Life, Weakness, Master of Engineering, CEO, Pharmaceutical industry, Management

ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.

Key Points: 
  • ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.
  • Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

Axion BioSystems Welcomes Biotech Industry Leader Kevin Gould as New CEO

Retrieved on: 
Monday, May 16, 2022 - 5:00am
Research, Medical Devices, Medical Supplies, Genetics, Biotechnology, Health, Other Science, Science, Oncology, Senior, Work, Investment, Biophysical environment, ESG, Electronics, Multimedia, Biology, Axion, Efficiency, Cell, Research, Sustainable Development Goal 9, Time, Sustainable Development Goals, Thermo Fisher Scientific, B cell, Bio-Techne, Drug discovery, CEO, Pharmaceutical industry, Management, Fine chemical, BioSystems, Social

Axion BioSystems, a leading life science tools company focused on advanced live-cell assay platforms , announces that Kevin Gould has been appointed the companys Chief Executive Officer, effective immediately.

Key Points: 
  • Axion BioSystems, a leading life science tools company focused on advanced live-cell assay platforms , announces that Kevin Gould has been appointed the companys Chief Executive Officer, effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20220515005001/en/
    Kevin takes over today from Axions long-time CEO Tom OBrien, who will be retiring July 15th.
  • OBrien, who co-founded Axion BioSystems in 2008 with Chief Technical Officer Jim Ross, said that Gould is a natural fit for leading the company.
  • Kevins experience in the industry speaks for itself and his passion for driving biotech research forward is unparalleled.

PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma

Retrieved on: 
Sunday, May 15, 2022 - 6:24pm
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Online, BDA, Disease, Metabolism, Medicine, Dermatology, Efficacy, The New England Journal of Medicine, Inhaler, ClinicalTrials.gov, Mortality, AstraZeneca, Conference, Week, Nature Research, NDA, Safety, Biopharmaceutical, Papis Loveday, Immunology, Risk factor, Hospital, SCS, COPD, Protein Data Bank (file format), Clinical trial, Research, Thomas Ford Chipp, ICS, Journal of Asthma and Allergy, CDC, Growth, Death, Company, Budesonide, Salbutamol, Science, MDI, Gastroenterology, Observational study, Rheumatology, Child, Risk, ID, Ageing, Chronic lung disease, Atmosphere, Link, Global Initiative for Asthma, JAMA, Jean-Jacques Bourdin, ERS, Clare Lloyd, Degenerative disease, Diagnosis, Pharmaceutical industry, Silviculture, FEV1, Asthma, Patient

PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.

Key Points: 
  • PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
  • AstraZenecas ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.
  • Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
  • The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK.

ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference

Retrieved on: 
Sunday, May 15, 2022 - 7:15pm
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, RNA transfection, Population, American Thoracic Society, Disease, International Conference on Emerging Infectious Diseases, Primary ciliary dyskinesia, Cystic fibrosis, HBE, Patient, Lipid, Therapy, Liver, Bronchiectasis, Cell, Publication, ATS, Lists of diseases, Conference, SORT, CFTR, Recode, PCD, Lung, Tissue, Vaccine, DNAI1, LNP

Patients with PCD have a high burden of morbidity with chronic respiratory infections, bronchiectasis, and often develop respiratory failure.

Key Points: 
  • Patients with PCD have a high burden of morbidity with chronic respiratory infections, bronchiectasis, and often develop respiratory failure.
  • ReCode is developing a disease-modifying mRNA-based approach for the treatment of PCD caused by mutations in DNAI1, an essential gene for ciliary movement.
  • Full details from the data presented at ATS 2022 can be accessed via the Publications section on ReCodes website.
  • ReCode will also present new preclinical data from its mRNA-based therapeutic program for cystic fibrosis on Wednesday, May 18th.

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Retrieved on: 
Sunday, May 15, 2022 - 5:41pm
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pulmonary fibrosis, Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, International Conference on Afghanistan, London (2010), Patient, Principal investigator, Vital capacity, Phase, NEJM, American Thoracic Society, Diarrhea, The New England Journal of Medicine, PDE4B, Hope, Respiratory Medicine, FDA, Probability, Conference, ATS, PPF, Atmosphere, Board, Safety, Executive Office of the President of the United States, Boehringer Ingelheim, Idiopathic pulmonary fibrosis, IPF, FVC, Pharmaceutical industry, Medical device

In patients already taking antifibrotic therapy, the median changes in FVC were +2.7 mL for BI 1015550 and -59.2 mL in the placebo arm.

Key Points: 
  • In patients already taking antifibrotic therapy, the median changes in FVC were +2.7 mL for BI 1015550 and -59.2 mL in the placebo arm.
  • There is >98% probability that BI 1015550 was superior to placebo in slowing down the worsening of lung function in people with IPF.
  • The Phase II results reinforce our confidence in BI 1015550 which will be accelerated into a pivotal Phase III program.
  • We will work with regulatory agencies and scientific communities to potentially bring the next generation of treatments to people living with pulmonary fibrosis as quickly as possible.

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

Retrieved on: 
Sunday, May 15, 2022 - 3:05pm
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology

Two podium presentations at AUA2022 on May 15 featured new analyses of data from the EMPOWUR 40-week extension trial of GEMTESA (vibegron) 75 mg.

Key Points: 
  • Two podium presentations at AUA2022 on May 15 featured new analyses of data from the EMPOWUR 40-week extension trial of GEMTESA (vibegron) 75 mg.
  • In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA was safe and well tolerated.
  • Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition, UUI episodes, and urgency episodes.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.